Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Oxyntomodulin (OXM) is a product of proglucagon processing in the intestine and the central nervous system. We reported that intracerebroventricular (ICV) and intranuclear administration of OXM caused an inhibition of food intake in rats (Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, and Bloom SR. Endocrinology 142: 4244–4250, 2001). In this study, we investigated the effect of twice-daily ICV administration of OXM, 1 nmol, for 7 days. A pair-fed control was included. These animals were restricted to the food intake of the OXM group but injected twice daily with saline. OXM-treated animals gained significantly less weight than either control group ( day 8: OXM, 12.2 ± 1.9 g vs. pair fed, 21.0 ± 2.1 g; P < 0.005). OXM treatment caused a reduction in epididymal white adipose tissue (OXM, 1.13 ± 0.03 g vs. pair fed, 1.29 ± 0.04 g; P < 0.05) and interscapular brown adipose tissue (OXM, 0.15 ± 0.01 g vs. pair fed, 0.18 ± 0.01 g; P < 0.05) and increased core temperature compared with saline control, suggestive of enhanced energy expenditure. The food restriction-induced suppression in plasma TSH, seen in the pair-fed group, was prevented by OXM, potentially via increased release of hypothalamic TRH. In summary, ICV OXM causes reduced body weight gain and body adiposity following chronic administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Glucagon-like peptide-1 (GLP-1) is another product of proglucagon processing in the intestine and the CNS and is a potential satiety factor (25, 26) and regulator of energy homeostasis (10, 11, 14).”
BackgroundSelf-citationCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 1×
“Glucagon-like peptide-1 (GLP-1) is another product of proglucagon processing in the intestine and the CNS and is a potential satiety factor (25, 26) and regulator of energy homeostasis (10, 11, 14).”
BackgroundLeptin actions on food intake and body temperature are mediated by IL-1
Luheshi, G. N., Gardner, J. D., Rushforth, D. A., Loudon, A. S., & Rothwell, N. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.7047 · Cited by 362
Fekete, C., Légrádi, G., Mihály, E., Huang, Q.-H., Tatro, J. B., Rand, W. M., Emerson, C. H., & Lechan, R. M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-04-01550.2000 · Cited by 308
Meeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303 · cited 2×
“Repeated daily ICV injections of GLP-1 caused a significant inhibition in cumulative body weight gain in rats fed to a 4-h schedule (18).”
BackgroundSelf-citationBLAKE, N. G., ECKLAND, D. J. A., FOSTER, O. J. F., & LIGHTMAN, S. L. (1991) · Endocrinology · doi:10.1210/endo-129-5-2714 · Cited by 168 · cited 1×
“This reduces the secretion of TSH from the pituitary, which, in turn, causes a general reduction in thyroid function (4, 5, 20).”
BackgroundRondeel, J. M. M., Heide, R., de Greef, W. J., van Toor, H., van Haasteren, G. A. C., Klootwijk, W., & Visser, T. J. (2008) · Neuroendocrinology · doi:10.1159/000126248 · Cited by 99 · cited 1×
“This reduces the secretion of TSH from the pituitary, which, in turn, causes a general reduction in thyroid function (4, 5, 20).”
Background
Cited by
Gut hormones and the regulation of energy homeostasis
Murphy, K. G., & Bloom, S. R. (2006) · Nature · doi:10.1038/nature05484 · Cited by 778
Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans
Cohen, M. A., Ellis, S. M., Le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 472
Self-citationCentral Control of Body Weight and Appetite
Woods, S. C., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1630 · Cited by 458
Gastrointestinal hormones and food intake
Strader, A. D., & Woods, S. C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.10.043 · Cited by 447
Gut Hormones and Appetite Control
Wren, A. M., & Bloom, S. R. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.048 · Cited by 432
Self-citationThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372
Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363
Self-citationGastrointestinal hormones regulating appetite
Chaudhri, O., Small, C., & Bloom, S. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1856 · Cited by 346
Self-citationPeripheral Oxyntomodulin Reduces Food Intake and Body Weight Gain in Rats
Dakin, C. L., Small, C. J., Batterham, R. L., Neary, N. M., Cohen, M. A., Patterson, M., Ghatei, M. A., & Bloom, S. R. (2004) · Endocrinology · doi:10.1210/en.2003-1338 · Cited by 342
Self-citationGastrointestinal Satiety Signals
Chaudhri, O. B., Salem, V., Murphy, K. G., & Bloom, S. R. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100506 · Cited by 334
Self-citationRegulation of energy balance by a gut–brain axis and involvement of the gut microbiota
Bauer, P. V., Hamr, S. C., & Duca, F. A. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2083-z · Cited by 216
“administration of both GLP-1 [121] and OXM, a gut peptide produced from the proglucagon gene [122], increases energy expenditure in rodents.”
BackgroundThe role of gut hormones in the regulation of body weight and energy homeostasis
Karra, E., & Batterham, R. L. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.06.010 · Cited by 209
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
The L-cell in nutritional sensing and the regulation of appetite
Spreckley, E. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2015.00023 · Cited by 198
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
Gut Microbiota in Obesity and Undernutrition
de Clercq, N. C., Groen, A. K., Romijn, J. A., & Nieuwdorp, M. (2016) · Advances in Nutrition · doi:10.3945/an.116.012914 · Cited by 140
Cheng, C. Y. Y., Chu, J. Y. S., & Chow, B. K. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.178 · Cited by 98
“…al, 2003a, b; Batterham et al, 2002; Challis et al, 2003), glucagon-like peptide-1 (Glp1; Meeran et al, 1999; Tang-Christensen et al, 2001; Turton et al, 1996; Verdich et al, 2001; Yamamoto et al, 2003), and oxyntomodulin (Cohen et al, 2003; Dakin et al, 2002; Dakin et al, 2001; Dakin et al, 2004).”
BackgroundOxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86
“In pair-feeding experiments, it was more efficient than paired restrictions in food intake, suggesting that oxyntomodulin (and glucagon) may also increase energy expenditure [66].”
Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735019 · Cited by 81
“More recently, metabolic cage studies have confirmed that the increased oxygen consumption and energy expenditure effect of OXM is mediated through glucagon receptor signalling (29, 39, 40).”
BackgroundThe molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
Elvert, R., Herling, A. W., Bossart, M., Weiss, T., Zhang, B., Wenski, P., Wandschneider, J., Kleutsch, S., Butty, U., Kannt, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13212 · Cited by 42
“four-day period increased energy expenditure while reducing energy intake.(15) Also, co-administration of a GLP-1 agonist with a glucagon infusion resulted in an increase of energy expenditure in humans.”
BackgroundBowels control brain: gut hormones and obesity
Bewick, G. A. (2012) · Biochemia Medica · doi:10.11613/bm.2012.032 · Cited by 36
Corfe, B. M., Harden, C. J., Bull, M., & Garaiova, I. (2015) · Proceedings of the Nutrition Society · doi:10.1017/s0029665114001670 · Cited by 18
Metadata
- Authors
- Dakin, C. L., Small, C. J., Park, A. J., Seth, A., Ghatei, M. A., & Bloom, S. R.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2002-12-01
- Volume
- 283
- Issue
- 6
- Pages
- E1173-E1177
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2144166875
- Cited by
- 142
- References
- 8
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.